p.81 抽出テキスト

162. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381:841–851. https://doi.org/10.1056/NEJMoa1901118 163. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021;385:896–907. https://doi.org/10.1056/NEJMoa2108269 164. Sattar N, Lee MM, Kristensen SL, Branch KR, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021;9:653–662. https://doi.org/10.1016/S2213-8587(21) 00203-5 165. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–1289. https://doi.org/ 10.1016/S0140-6736(05)67528-9 166. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180–1188. https://doi.org/10.1001/jama.298.10.1180 167. Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab 2020;105: 1670–1681. https://doi.org/10.1210/clinem/dgz252 168. de Jong M, van der Worp HB, van der Graaf Y, Visseren FL, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol 2017;16:134. https://doi.org/10. 1186/s12933-017-0617-4 169. Lin M-H, Yang H-Y, Yen C-L, Wu C-Y, Jenq C-C, Kuo G, et al. Pioglitazone is associated with lower major adverse cardiovascular and cerebrovascular events than DPP4-inhibitors in diabetic patients with end-stage renal disease: a Taiwan Nationwide Cohort Study, 2006–2016. J Clin Med 2020;9:3578. https://doi.org/10. 3390/jcm9113578 170. Rydén L, Thráinsdóttir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive. Lancet 2007;369:189–190. https://doi.org/10.1016/S0140-6736(07) 60106-8 171. McGuire DK, Abdullah SM, See R, Snell PG, McGavock J, Szczepaniak LS, et al. Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function. Eur Heart J 2010;31: 2262–70. https://doi.org/10.1093/eurheartj/ehq228 172. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317–1326. https://doi.org/10.1056/NEJMoa1307684 173. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327–1335. https://doi.org/10.1056/NEJMoa1305889 174. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232–242. https://doi.org/10.1056/NEJMoa1501352 175. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019;321:69–79. https://doi.org/10.1001/jama.2018.18269 176. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014;130:1579–1588. https://doi.org/10.1161/ CIRCULATIONAHA.114.010389 177. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385:2067–2076. https://doi.org/10.1016/S0140-6736(14)62225-X 178. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 2016;1:126–135. https://doi.org/10.1001/jamacardio.2016.0103 179. McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, et al. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation 2019; 139:351–361. https://doi.org/10.1161/CIRCULATIONAHA.118.038352 180. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 2019;322:1155–1166. https://doi.org/10.1001/jama.2019.13772 181. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377: 723–732. https://doi.org/10.1056/NEJMoa1615692 182. Gore MO, McGuire DK. Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. Eur Heart J 2011;32:1832–1834. https://doi.org/10.1093/eurheartj/ehr019 183. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865. https://doi.org/10.1016/S0140-6736(98)07037-8 184. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 2017;60:1620–1629. https://doi.org/10.1007/s00125-017-4337-9 185. Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol 2019;18:1–16. https://doi.org/10.1186/ s12933-019-0900-7 186. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32:1900–1908. https://doi.org/10.1093/eurheartj/ ehr077 187. Mellbin LG, Rydén L, Riddle MC, Probstfield J, Rosenstock J, Díaz R, et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013;34:3137–3144. https://doi.org/10.1093/eurheartj/eht332 188. ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. Diabetes Care 2015;38:22–28. https://doi.org/10.2337/dc14-1329 189. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384: 117–128. https://doi.org/10.1056/NEJMoa2030183 190. Tuttle KR, Brosius FC III, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJ, et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation. Diabetes 2021; 70:1–16. https://doi.org/10.2337/dbi20-0040 191. Ferrannini G, De Bacquer D, Vynckier P, De Backer G, Gyberg V, Kotseva K, et al. Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys. Cardiovasc Diabetol 2021;20:1–12. https://doi.org/10.1186/s12933-021-01233-6 192. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension 2020;75:1334–1357. https://doi.org/10.1161/HYPERTENSIONAHA. 120.15026 193. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018;39:3021–3104. https:// doi.org/10.1093/eurheartj/ehy339 194. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation 2011;123: 2799–2810. https://doi.org/10.1161/CIRCULATIONAHA.110.016337 195. Grenet G, Le H, Bejan-Angoulvant T, Erpeldinger S, Boussageon R, Kassaï B, et al. Association between difference in blood pressure reduction and risk of cardiovascular events in a type 2 diabetes population: a meta-regression analysis. Diabetes Metab 2019;45:550–556. https://doi.org/10.1016/j.diabet.2019.05.003 196. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015;313:603–615. https://doi.org/10.1001/jama.2014.18574 197. Arima H, Anderson C, Omae T, Woodward M, MacMahon S, Mancia G, et al. Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial. J Neurol Neurosurg Psychiatry 2014;85:1284–1285. https://doi.org/10.1136/jnnp-2014-307856 198. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am College Cardiol 2012;59:74–83. https://doi.org/10.1016/j.jacc. 2011.09.040 199. Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 2014;37:1721–1728. https://doi. org/10.2337/dc13-2334 200. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563–1574. https://doi.org/10.1056/NEJMoa1001282 201. Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Emrich I, et al. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J Hypertension 2021;39:766–774. https://doi.org/10.1097/HJH.0000000000002697 202. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10–should blood pressure management differ

ESC Guidelines                                                                                                                                                                                          4123

Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026